Cite
HARVARD Citation
Alten, R. et al. (n.d.). FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. Annals of the rheumatic diseases. pp. 612-613. [Online].